Hydrocortisone

Identification

Name

Hydrocortisone

Accession Number

DB00741  (APRD01019, DB07886)

Type

Small Molecule

Groups

Approved, Vet approved

Description

The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. [PubChem]

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB00741 (Hydrocortisone)

×

Close

Synonyms

• (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
• (11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
• 11beta-hydrocortisone
• 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
• 11β-hydrocortisone
• 17-Hydroxycorticosterone
• 4-Pregnen-11beta,17alpha,21-triol-3,20-dione
• Cortisol
• Hidrocortisona
• Hydrocortisone
• Hydrocortisonum
• Kendall's compound F
• Reichstein's substance M

External IDs

NSC-10483

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Hydrocortisone aceponate	2340UP1L2G	74050-20-7	MFBMYAOAMQLLPK-FZNHGJLXSA-N
Hydrocortisone acetate	3X7931PO74	50-03-3	ALEXXDVDDISNDU-JZYPGELDSA-N
Hydrocortisone butyrate	05RMF7YPWN	13609-67-1	BMCQMVFGOVHVNG-TUFAYURCSA-N
Hydrocortisone cypionate	4XDY25L70B	508-99-6	DLVOSEUFIRPIRM-KAQKJVHQSA-N
Hydrocortisone phosphate	2Y87E22X71	3863-59-0	BGSOJVFOEQLVMH-VWUMJDOOSA-N
Hydrocortisone probutate	O6550D6K3A	72590-77-3	FOGXJPFPZOHSQS-AYVLZSQQSA-N
Hydrocortisone sodium phosphate	0388G963HY	6000-74-4	RYJIRNNXCHOUTQ-OJJGEMKLSA-L
Hydrocortisone sodium succinate	50LQB69S1Z	125-04-2	HHZQLQREDATOBM-CODXZCKSSA-M
Hydrocortisone valerate	68717P8FUZ	57524-89-7	FZCHYNWYXKICIO-FZNHGJLXSA-N

Product Images

PreviousNext

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
A-hydrocort Inj 1000mg/8ml	Powder, for solution	1 g	Intramuscular; Intravenous	Hospira, Inc.	1993-12-31	2012-08-03
A-hydrocort Inj 100mg/2ml	Powder, for solution	100 mg	Intramuscular; Intravenous	Hospira, Inc.	1992-12-31	2012-08-03
A-hydrocort Inj 250mg/2ml	Powder, for solution	250 mg	Intramuscular; Intravenous	Hospira, Inc.	1992-12-31	2012-08-03
A-hydrocort Inj 500mg/4ml	Powder, for solution	500 mg	Intramuscular; Intravenous	Hospira, Inc.	1992-12-31	2012-08-03
Alocort 1% - Crm	Cream	1 %	Topical	Ucb Inc	1996-12-06	1998-04-21
Aquacort Lotion 2.5%	Lotion	2.5 %	Topical	Merit Industries Inc.	1992-12-31	2002-05-14
Barriere HC 1%	Cream; Jelly	1 %	Topical	Allen & Hanburys A Glaxo Canada Ltd. Co.	1979-12-31	1998-07-29
Cortamed Ont 25 mg/g	Ointment	2.5 %	Ophthalmic	Sandoz Canada Incorporated	1992-12-31	Not applicable
Cortate Crm 1%	Cream	10 mg	Topical	Schering Plough	1980-12-31	2013-07-31
Cortate Ont 1%	Ointment	10 mg	Topical	Schering Plough	1980-12-31	2013-07-31

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
A-hydrocort	Injection, powder, lyophilized, for solution	100 mg/2mL	Intramuscular; Intravenous	Hospira, Inc.	2011-05-12	2017-08-04
Ala Scalp	Lotion	20 mg/mL	Topical	Crown Laboratories	1973-02-28	Not applicable
Alacort	Cream	25 mg/g	Topical	Crown Laboratories	1973-03-09	Not applicable
Alacort	Cream	10 mg/g	Topical	Crown Laboratories	1973-03-09	Not applicable
Anusol HC	Cream	25 mg/g	Topical	Salix Pharmaceuticals	1984-06-06	Not applicable
Colocort	Suspension	100 mg/60mL	Rectal	Paddock Laboratories, Inc.	1999-12-31	Not applicable
Home PapKit	Cream	25 mg/g	Topical	International Brand Management, Llc	2016-09-15	Not applicable
Hydrocortisone	Cream	25 mg/g	Topical	Aidarex Pharmaceuticals LLC	2006-03-31	Not applicable
Hydrocortisone	Tablet	5 mg/1	Oral	Amerincan Health Packaging	2014-06-16	Not applicable
Hydrocortisone	Tablet	5 mg/1	Oral	Kaiser Foundations Hospitals	2010-03-05	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
1% Hydrocortisone	Cream	1 g/100g	Topical	Yuyao Jessie Commodity Co.,Ltd.	2015-12-01	Not applicable
999 Itch Relieving	Ointment	1 g/100g	Topical	Guangdong CR. Shunfeng Pharmaceutical Co Ltd	1989-07-20	Not applicable
999 Itch Relieving	Ointment	1 g/100g	Topical	Guangdong CR. Shunfeng Pharmaceutical Co Ltd	1989-07-20	Not applicable
Advanced Anti-itch Therapy	Soap	1 g/100g	Topical	CVS Health	2016-06-10	Not applicable
Advanced Hydrocortisone	Cream	10 mg/g	Topical	Ultra Seal Corporation	2011-04-05	Not applicable
Aftate Hydrocortisone Cream	Cream	1 g/100g	Topical	Sabel Med Llc	2016-05-01	Not applicable
Ana Cool Rapid Soothing Cooling Formula	Cream	10 mg/g	Topical	Ana Cool, Llc	2015-11-25	Not applicable
Anti Itch	Lotion	1 g/100g	Topical	Walgreen	2012-03-27	Not applicable
Anti Itch	Cream	1 g/100g	Topical	Rite Aid	2013-09-11	Not applicable
Anti itch	Cream	1 g/100g	Topical	Rite Aid	2009-02-09	2017-11-14

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Acetasol HC	Hydrocortisone (1.1 g/100mL) + Acetic acid (2.41 g/100mL)	Solution	Auricular (otic)	Actavis Pharma Company	2002-09-10	Not applicable
Actinac Pwr	Hydrocortisone acetate (40 mg) + Allantoin (24 mg) + Chloramphenicol (40 mg) + Nicoboxil (24 mg) + Sulfur (320 mg)	Powder	Topical	Roussel Canada Inc.	1978-12-31	1996-09-09
Actinac Pws	Hydrocortisone acetate (40 mg) + Allantoin (24 mg) + Chloramphenicol (40 mg) + Nicoboxil (24 mg) + Sulfur (320 mg)	Powder, for solution	Topical	Hoechst Roussel Canada Inc.	1994-12-31	2001-07-20
Alocane	Hydrocortisone acetate (5 mg/mL) + Lidocaine hydrochloride (945 mg/mL)	Ointment	Topical	Product Quest	2014-11-11	Not applicable
Analpram HC	Hydrocortisone acetate (25 mg/mL) + Pramoxine hydrochloride (10 mg/mL)	Lotion	Topical	Ferndale Laboratories, Inc.	1996-01-01	2016-12-31
Analpram HC	Hydrocortisone acetate (25 mg/mL) + Pramoxine hydrochloride (10 mg/mL)	Lotion	Topical	Sebela Pharmaceuticals Inc.	1996-01-01	Not applicable
Analpram HC	Hydrocortisone acetate (10 mg/g) + Pramoxine hydrochloride (10 mg/g)	Cream	Topical	Ferndale Laboratories, Inc.	1985-12-23	2016-09-30
Analpram HC	Hydrocortisone acetate (10 mg/g) + Pramoxine hydrochloride (10 mg/g)	Cream	Topical	Sebela Pharmaceuticals Inc.	1985-12-23	Not applicable
Anodan-HC 10mg Suppositories	Hydrocortisone acetate (10 mg) + Zinc sulfate (10 mg)	Suppository	Rectal	Odan Laboratories Ltd	1998-08-13	Not applicable
Anodan-HC Ointment	Hydrocortisone acetate (0.5 %) + Zinc sulfate (0.5 %)	Ointment	Rectal; Topical	Odan Laboratories Ltd	1995-12-31	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Acella Hydrocortisone Acetate - Pramoxine Singles	Hydrocortisone acetate (2.5 g/100g) + Pramocaine (1 g/100g)	Cream	Topical	Acella Pharmaceuticals, LLC	2010-11-08	2017-08-17
Ala Quin	Hydrocortisone (5 mg/g) + Clioquinol (30 mg/g)	Cream	Topical	Crown Laboratories	1970-08-19	Not applicable
Alcortin	Hydrocortisone (2 g/100g) + Diiodohydroxyquinoline (1 g/100g)	Gel	Topical	Primus Pharmaceuticals	2003-07-25	Not applicable
Alcortin A	Hydrocortisone acetate (20 mg/g) + Aloe Polysaccharide (10 mg/g) + Diiodohydroxyquinoline (10 mg/g)	Gel	Topical	Novum Pharma, Llc	2015-03-01	Not applicable
Ana-Lex	Hydrocortisone acetate (20 mg/g) + Lidocaine hydrochloride (20 mg/g)	Cream	Topical	Avion Pharmaceuticals, Llc	2008-02-28	Not applicable
Analpram Advanced	Hydrocortisone acetate + Pramoxine hydrochloride	Kit		Sebela Pharmaceuticals Inc.	2010-10-01	2017-02-28
Analpram Advanced	Hydrocortisone acetate + Pramoxine hydrochloride	Kit		Ferndale Laboratories, Inc.	2010-10-01	2016-12-31
Analpram Advanced	Hydrocortisone acetate + Pramoxine hydrochloride	Kit	Oral	Sebela Pharmaceuticals Inc.	2010-10-01	2017-02-23
Analpram Advanced	Hydrocortisone acetate + Pramoxine hydrochloride	Kit		Sebela Pharmaceuticals Inc.	2010-08-01	2017-02-28
Analpram Advanced	Hydrocortisone acetate + Pramoxine hydrochloride	Kit		Ferndale Laboratories, Inc.	2010-10-01	2016-04-30

International/Other Brands

Acticort / Aeroseb HC / Ala-Scalp / Algicirtis / Aquanil HC / Beta-HC / Cetacort / Cortaid / Delacort / Ficortril / Genacort / Glycort / Komed HC / Lacticare HC / Lubricort / Medicort / Meusicort / Micort-HC / Mildison / Nogenic HC / Nutracort / Nystaform-HC / Otocort / Penecort / Permicort / Polcort H / Preparation H Hydrocortisone Cream / Prepcort / Prevex HC / Proctocort / Proctocream / Protocort / Remederm HC / Sanatison / Scalpicin Capilar / Schericur / Sigmacort / Synacort / Systral Hydrocort / Timocort

Categories

• 11-Hydroxycorticosteroids
• 17-Hydroxycorticosteroids
• Administration, Topical
• Adrenal Cortex Hormones
• Adrenals
• Aerosols
• Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
• Alimentary Tract and Metabolism
• Anti-Inflammatory Agents
• Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents
• Cardiovascular System
• Corticosteroids
• Corticosteroids Acting Locally
• Corticosteroids for Local Oral Treatment
• Corticosteroids for Systemic Use
• Corticosteroids for Systemic Use, Plain
• Corticosteroids, Dermatological Preparations
• Corticosteroids, Moderately Potent (Group II)
• Corticosteroids, Potent (Group III)
• Corticosteroids, Weak (Group I)
• Cytochrome P-450 CYP3A Inducers
• Cytochrome P-450 CYP3A4 Inducers
• Cytochrome P-450 CYP3A4 Inducers (weak)
• Cytochrome P-450 Enzyme Inducers
• Cytochrome P-450 Enzyme Inhibitors
• Dermatologicals
• Glucocorticoids
• Hormones
• Hormones, Hormone Substitutes, and Hormone Antagonists
• Hydroxycorticosteroids
• Hyperglycemia-Associated Agents
• Immunosuppressive Agents
• Intestinal Antiinflammatory Agents
• Nasal Preparations
• OAT3 Substrates
• Ophthalmological and Otological Preparations
• Ophthalmologicals
• Otologicals
• P-glycoprotein/ABCB1 Substrates
• Pregnanes
• Pregnenediones
• Pregnenes
• Sensory Organs
• Steroids
• Stomatological Preparations
• Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins
• Vasoprotectives

UNII

WI4X0X7BPJ

CAS number

50-23-7

Weight

Average: 362.4599
Monoisotopic: 362.20932407

Chemical Formula

C₂₁H₃₀O₅

InChI Key

JYGXADMDTFJGBT-VWUMJDOOSA-N

InChI

InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

IUPAC Name

(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one

SMILES

[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

Associated Conditions

• Acute Gouty Arthritis
• Allergic Rhinitis (AR)
• Allergic corneal marginal ulcers
• Ankylosing Spondylitis (AS)
• Anterior Segment Inflammation
• Aspiration Pneumonitis
• Asthma Bronchial
• Atopic Dermatitis (AD)
• Berylliosis
• Bullous dermatitis herpetiformis
• Congenital Adrenal Hyperplasia (CAH)
• Conjunctivitis, Seasonal Allergic
• Corneal Inflammation
• Crohn's Disease (CD)
• Dermatitis, Contact
• Dermatomyositis
• Dermatosis
• Drug hypersensitivity reaction
• Epicondylitis
• Erythroblastopenia
• Hypercalcemia of Malignancy
• Idiopathic Thrombocytopenic Purpura (ITP)
• Iridocyclitis
• Iritis
• Leukaemia, Acute
• Leukemias
• Loeffler's syndrome
• Malignant Lymphomas
• Mycosis Fungoides (MF)
• Ophthalmia, Sympathetic
• Optic Neuritis
• Pemphigus
• Primary adrenocortical insufficiency
• Proteinuria
• Psoriatic Arthritis
• Rheumatic heart disease, unspecified
• Rheumatoid Arthritis
• Rheumatoid Arthritis, Juvenile
• Secondary adrenocortical insufficiency
• Secondary thrombocytopenia
• Serum Sickness
• Severe Seborrheic Dermatitis
• Stevens Johnson Syndrome
• Synovitis
• Systemic Lupus Erythematosus (SLE)
• Trichinosis
• Tuberculous Meningitis
• Ulcerative Colitis (UC)
• Acquired immune hemolytic anemia
• Acute Bursitis
• Acute Tenosynovitis
• Diffuse posterior uveitis
• Disseminated Pulmonary Tuberculosis
• Exfoliative erythroderma
• Fulminating Pulmonary Tuberculosis
• Non-suppurative Thyroiditis
• Severe Psoriasis
• Subacute Bursitis
• Symptomatic Sarcoidosis
• Systemic Dermatomyositis
• Varicella-zoster virus acute retinal necrosis

Pharmacodynamics

Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.

Mechanism of action

Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

Target	Actions	Organism
AGlucocorticoid receptor	agonist	Human
AAnnexin A1	agonist	Human
UCorticosteroid 11-beta-dehydrogenase isozyme 2	Not Available	Human
U3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1	Not Available	Human

Absorption

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Volume of distribution

Not Available

Protein binding

95%

Metabolism

Primarily hepatic via CYP3A4

• Hydrocortisone
  6-beta-hydrocortisol

Route of elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Half life

6-8 hours

Clearance

Not Available

Toxicity

Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
17-alpha-hydroxylase deficiency (CYP17)	Disease
Steroidogenesis	Metabolic
Corticotropin Activation of Cortisol Production	Signaling
Corticosterone methyl oxidase I deficiency (CMO I)	Disease
Steroidogenesis	Metabolic
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency	Disease
21-hydroxylase deficiency (CYP21)	Disease
Apparent mineralocorticoid excess syndrome	Disease
3-Beta-Hydroxysteroid Dehydrogenase Deficiency	Disease
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH	Disease
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase Deficiency	Disease
11-beta-hydroxylase deficiency (CYP11B1)	Disease
Corticosterone methyl oxidase II deficiency - CMO II	Disease

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE	The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Hydrocortisone.	Experimental
(4R)-limonene	The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Hydrocortisone.	Investigational
1,10-Phenanthroline	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with 1,10-Phenanthroline.	Experimental
2,4-thiazolidinedione	The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Hydrocortisone.	Investigational
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Hydrocortisone.	Approved, Investigational
Acemetacin	The risk or severity of adverse effects can be increased when Acemetacin is combined with Hydrocortisone.	Approved, Experimental, Investigational
Acetaminophen	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Acetaminophen.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational, Withdrawn
Acetyl sulfisoxazole	The metabolism of Hydrocortisone can be decreased when combined with Acetyl sulfisoxazole.	Approved, Vet Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Hydrocortisone.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Hydrocortisone.	Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Hydrocortisone.	Approved
AICA ribonucleotide	The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydrocortisone.	Experimental, Investigational
Alclofenac	The risk or severity of adverse effects can be increased when Alclofenac is combined with Hydrocortisone.	Approved, Withdrawn
Aldesleukin	Hydrocortisone may decrease the antineoplastic activities of Aldesleukin.	Approved
Allicin	The therapeutic efficacy of Allicin can be decreased when used in combination with Hydrocortisone.	Investigational
Almasilate	The bioavailability of Hydrocortisone can be decreased when combined with Almasilate.	Approved, Experimental
Alminoprofen	The risk or severity of adverse effects can be increased when Alminoprofen is combined with Hydrocortisone.	Experimental
Alogliptin	The therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrocortisone.	Approved
Aloglutamol	The bioavailability of Hydrocortisone can be decreased when combined with Aloglutamol.	Approved
Aloxiprin	The risk or severity of adverse effects can be increased when Aloxiprin is combined with Hydrocortisone.	Experimental
Aluminium	The bioavailability of Hydrocortisone can be decreased when combined with Aluminium.	Approved, Investigational
Aluminium acetoacetate	The bioavailability of Hydrocortisone can be decreased when combined with Aluminium acetoacetate.	Experimental
Aluminium glycinate	The bioavailability of Hydrocortisone can be decreased when combined with Aluminium glycinate.	Experimental
Aluminum hydroxide	The bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.	Approved, Investigational
Ambenonium	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ambenonium.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Hydrocortisone.	Approved
Amiodarone	The metabolism of Hydrocortisone can be decreased when combined with Amiodarone.	Approved, Investigational
Amphotericin B	Hydrocortisone may increase the hypokalemic activities of Amphotericin B.	Approved, Investigational
Andrographolide	The risk or severity of adverse effects can be increased when Andrographolide is combined with Hydrocortisone.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with Hydrocortisone.	Investigational
Anthrax immune globulin human	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Anthrax immune globulin human.	Approved
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Hydrocortisone.	Approved, Investigational
Antrafenine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Antrafenine.	Approved
Apalutamide	The serum concentration of Hydrocortisone can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apocynin	The risk or severity of adverse effects can be increased when Apocynin is combined with Hydrocortisone.	Investigational
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Hydrocortisone.	Approved, Investigational
Aprepitant	The serum concentration of Hydrocortisone can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone.	Approved, Investigational
Asunaprevir	The serum concentration of Asunaprevir can be decreased when it is combined with Hydrocortisone.	Approved, Investigational, Withdrawn
Atazanavir	The metabolism of Hydrocortisone can be decreased when combined with Atazanavir.	Approved, Investigational
Atomoxetine	The metabolism of Hydrocortisone can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Atorvastatin.	Approved
Atracurium besylate	Atracurium besylate may increase the adverse neuromuscular activities of Hydrocortisone.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Hydrocortisone.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Hydrocortisone.	Approved
Azosemide	Hydrocortisone may increase the hypokalemic activities of Azosemide.	Investigational
Bacillus calmette-guerin substrain connaught live antigen	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bacillus calmette-guerin substrain connaught live antigen.	Approved, Investigational
Bacillus calmette-guerin substrain tice live antigen	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bacillus calmette-guerin substrain tice live antigen.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Hydrocortisone.	Investigational
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone.	Approved, Investigational
Bazedoxifene	The serum concentration of Hydrocortisone can be increased when it is combined with Bazedoxifene.	Approved, Investigational
BCG vaccine	The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Hydrocortisone.	Investigational
Bempedoic acid	The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Hydrocortisone.	Investigational
Bendazac	The risk or severity of adverse effects can be increased when Bendazac is combined with Hydrocortisone.	Experimental
Bendroflumethiazide	Hydrocortisone may increase the hypokalemic activities of Bendroflumethiazide.	Approved
Benorilate	The risk or severity of adverse effects can be increased when Benorilate is combined with Hydrocortisone.	Experimental
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Hydrocortisone.	Withdrawn
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Benzthiazide	Hydrocortisone may increase the hypokalemic activities of Benzthiazide.	Approved
Benzydamine	The risk or severity of adverse effects can be increased when Benzydamine is combined with Hydrocortisone.	Approved
Bevonium	The risk or severity of adverse effects can be increased when Bevonium is combined with Hydrocortisone.	Experimental
Bismuth Subcitrate	The bioavailability of Hydrocortisone can be decreased when combined with Bismuth Subcitrate.	Approved, Investigational
Bismuth subnitrate	The bioavailability of Hydrocortisone can be decreased when combined with Bismuth subnitrate.	Approved
Boceprevir	The metabolism of Hydrocortisone can be decreased when combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The metabolism of Hydrocortisone can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Hydrocortisone can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Hydrocortisone.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Hydrocortisone.	Approved, Investigational
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Hydrocortisone.	Approved
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydrocortisone.	Approved, Investigational
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with Hydrocortisone.	Investigational
Bufexamac	The risk or severity of adverse effects can be increased when Bufexamac is combined with Hydrocortisone.	Approved, Experimental
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Hydrocortisone.	Investigational, Withdrawn
Bumadizone	The risk or severity of adverse effects can be increased when Bumadizone is combined with Hydrocortisone.	Experimental
Bumetanide	Hydrocortisone may increase the hypokalemic activities of Bumetanide.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Hydrocortisone.	Approved
Calcitriol	The therapeutic efficacy of Calcitriol can be decreased when used in combination with Hydrocortisone.	Approved, Nutraceutical
Calcium Carbonate	The bioavailability of Hydrocortisone can be decreased when combined with Calcium Carbonate.	Approved, Investigational
Calcium silicate	The bioavailability of Hydrocortisone can be decreased when combined with Calcium silicate.	Experimental
Canagliflozin	The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocortisone.	Approved
Capromab pendetide	Hydrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.	Approved
Capsaicin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Capsaicin.	Approved
Carbamazepine	The serum concentration of Hydrocortisone can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbaspirin calcium	The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Hydrocortisone.	Experimental, Investigational
Carbutamide	The therapeutic efficacy of Carbutamide can be decreased when used in combination with Hydrocortisone.	Experimental
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Hydrocortisone.	Approved, Vet Approved, Withdrawn
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Hydrocortisone.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with Hydrocortisone.	Approved, Investigational
Ceritinib	The serum concentration of Hydrocortisone can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Hydrocortisone.	Approved, Withdrawn
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Hydrocortisone.	Approved, Investigational, Vet Approved
Chlorothiazide	Hydrocortisone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of Hydrocortisone can be increased when it is combined with Chlorotrianisene.	Investigational, Withdrawn
Chlorphenesin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Chlorphenesin.	Approved, Vet Approved, Withdrawn
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Chlorthalidone	Hydrocortisone may increase the hypokalemic activities of Chlorthalidone.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Hydrocortisone.	Approved
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrocortisone.	Experimental
Cimicoxib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cimicoxib.	Investigational
Cinoxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cinoxacin.	Approved, Investigational, Withdrawn
Ciprofloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ciprofloxacin.	Approved, Investigational
Cisplatin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Cisplatin.	Approved
Clarithromycin	The metabolism of Hydrocortisone can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Hydrocortisone can be decreased when combined with Clemastine.	Approved, Investigational
Clodronic Acid	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clodronic Acid.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with Hydrocortisone.	Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).	Approved
Clotrimazole	The metabolism of Hydrocortisone can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Cobicistat	The metabolism of Hydrocortisone can be decreased when combined with Cobicistat.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Hydrocortisone.	Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Hydrocortisone.	Approved, Investigational
Conjugated estrogens	The serum concentration of Hydrocortisone can be increased when it is combined with Conjugated estrogens.	Approved
Corticorelin ovine triflutate	The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Hydrocortisone.	Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).	Approved
Coumaphos	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Coumaphos.	Vet Approved
Crizotinib	The metabolism of Hydrocortisone can be decreased when combined with Crizotinib.	Approved
Curcumin	The metabolism of Hydrocortisone can be decreased when combined with Curcumin.	Approved, Investigational
Cyclopenthiazide	Hydrocortisone may increase the hypokalemic activities of Cyclopenthiazide.	Experimental
Cyclosporine	The metabolism of Hydrocortisone can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Hydrocortisone.	Approved
Dabrafenib	The serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Daidzein	The serum concentration of Hydrocortisone can be increased when it is combined with Daidzein.	Experimental
Danazol	Hydrocortisone may increase the fluid retaining activities of Danazol.	Approved
Darunavir	The metabolism of Hydrocortisone can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.	Approved, Investigational
Decamethonium	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Decamethonium.	Approved
Deferasirox	The serum concentration of Hydrocortisone can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Hydrocortisone can be decreased when combined with Delavirdine.	Approved
Demecarium	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Demecarium.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Hydrocortisone.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Hydrocortisone.	Investigational
Dersalazine	The risk or severity of adverse effects can be increased when Dersalazine is combined with Hydrocortisone.	Investigational
Dexibuprofen	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexibuprofen.	Approved, Investigational
Dexketoprofen	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexketoprofen.	Approved, Investigational
Dichlorvos	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dichlorvos.	Vet Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Hydrocortisone.	Approved, Vet Approved
Dienestrol	The serum concentration of Hydrocortisone can be increased when it is combined with Dienestrol.	Approved, Investigational
Diethylstilbestrol	The serum concentration of Hydrocortisone can be increased when it is combined with Diethylstilbestrol.	Approved, Investigational
Difenpiramide	The risk or severity of adverse effects can be increased when Difenpiramide is combined with Hydrocortisone.	Experimental
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Hydrocortisone.	Approved, Investigational
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Hydrocortisone.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Hydrocortisone.	Approved, Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Hydrocortisone.	Experimental
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Hydrocortisone.	Approved, Investigational
Diltiazem	The metabolism of Hydrocortisone can be decreased when combined with Diltiazem.	Approved, Investigational
Dipivefrin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dipivefrin.	Approved
Distigmine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Distigmine.	Experimental
Donepezil	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Donepezil.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Hydrocortisone.	Approved, Investigational
Doxycycline	The metabolism of Hydrocortisone can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronedarone	The metabolism of Hydrocortisone can be decreased when combined with Dronedarone.	Approved
Drospirenone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with Hydrocortisone.	Withdrawn
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with Hydrocortisone.	Investigational
E-6201	The risk or severity of adverse effects can be increased when E-6201 is combined with Hydrocortisone.	Investigational
Echothiophate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Echothiophate.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Hydrocortisone.	Approved
Edrophonium	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Edrophonium.	Approved
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone.	Approved
Englitazone	The therapeutic efficacy of Englitazone can be decreased when used in combination with Hydrocortisone.	Experimental
Enoxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Enoxacin.	Approved, Investigational
Enzalutamide	The serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide.	Approved
Epimestrol	The serum concentration of Hydrocortisone can be increased when it is combined with Epimestrol.	Experimental
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with Hydrocortisone.	Approved
Epitizide	Hydrocortisone may increase the hypokalemic activities of Epitizide.	Experimental
Equol	The serum concentration of Hydrocortisone can be increased when it is combined with Equol.	Investigational
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Hydrocortisone.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Hydrocortisone.	Approved
Erythromycin	The metabolism of Hydrocortisone can be decreased when combined with Erythromycin.	Approved, Investigational, Vet Approved
Estradiol	The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol.	Approved, Investigational, Vet Approved
Estradiol acetate	The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol acetate.	Approved, Investigational, Vet Approved
Estradiol cypionate	The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol cypionate.	Approved, Investigational, Vet Approved
Estradiol valerate	The serum concentration of Hydrocortisone can be increased when it is combined with Estradiol valerate.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Hydrocortisone can be increased when it is combined with Estriol.	Approved, Investigational, Vet Approved
Estrogens, esterified	The serum concentration of Hydrocortisone can be increased when it is combined with Estrogens, esterified.	Approved
Estrone	The serum concentration of Hydrocortisone can be increased when it is combined with Estrone.	Approved
Etacrynic acid	Hydrocortisone may increase the hypokalemic activities of Etacrynic acid.	Approved, Investigational
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone.	Approved, Investigational
Ethenzamide	The risk or severity of adverse effects can be increased when Ethenzamide is combined with Hydrocortisone.	Experimental
Ethinyl Estradiol	The serum concentration of Hydrocortisone can be increased when it is combined with Ethinyl Estradiol.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with Hydrocortisone.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with Hydrocortisone.	Approved, Investigational
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with Hydrocortisone.	Approved, Investigational
Evening primrose oil	The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Hydrocortisone.	Investigational, Nutraceutical
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Hydrocortisone.	Approved
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Exisulind	The risk or severity of adverse effects can be increased when Exisulind is combined with Hydrocortisone.	Investigational
Felbinac	The risk or severity of adverse effects can be increased when Felbinac is combined with Hydrocortisone.	Experimental
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with Hydrocortisone.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Hydrocortisone.	Approved
Fenthion	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fenthion.	Vet Approved
Fentiazac	The risk or severity of adverse effects can be increased when Fentiazac is combined with Hydrocortisone.	Experimental
Feprazone	The risk or severity of adverse effects can be increased when Feprazone is combined with Hydrocortisone.	Experimental
Ferulic acid	The risk or severity of adverse effects can be increased when Ferulic acid is combined with Hydrocortisone.	Experimental
Fingolimod	Hydrocortisone may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
Fish oil	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fish oil.	Approved, Nutraceutical
Fleroxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Hydrocortisone.	Approved, Withdrawn
Fluconazole	The metabolism of Hydrocortisone can be decreased when combined with Fluconazole.	Approved, Investigational
Flumequine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Flumequine.	Withdrawn
Flunixin	The risk or severity of adverse effects can be increased when Flunixin is combined with Hydrocortisone.	Vet Approved
Flunoxaprofen	The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Hydrocortisone.	Experimental
Fluoxymesterone	Hydrocortisone may increase the fluid retaining activities of Fluoxymesterone.	Approved, Illicit
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Hydrocortisone.	Approved, Investigational
Fluvastatin	The serum concentration of Fluvastatin can be increased when it is combined with Hydrocortisone.	Approved
Fluvoxamine	The metabolism of Hydrocortisone can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Hydrocortisone can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Hydrocortisone can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Hydrocortisone can be decreased when it is combined with Fosphenytoin.	Approved, Investigational
Furosemide	Hydrocortisone may increase the hypokalemic activities of Furosemide.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Hydrocortisone can be increased when it is combined with Fusidic Acid.	Approved, Investigational
G17DT	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with G17DT.	Investigational
Galantamine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Galantamine.	Approved
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gallamine Triethiodide.	Approved
Garenoxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Garenoxacin.	Investigational
Gatifloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin.	Approved, Investigational
Gemifloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of Hydrocortisone can be increased when it is combined with Genistein.	Investigational
GI-5005	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with GI-5005.	Investigational
Ginkgo biloba	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ginkgo biloba.	Approved, Investigational, Nutraceutical
Ginseng	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ginseng.	Approved, Investigational, Nutraceutical
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrocortisone.	Investigational, Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydrocortisone.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrocortisone.	Approved
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
GLPG-0492	Hydrocortisone may increase the fluid retaining activities of GLPG-0492.	Investigational
Glyburide	The therapeutic efficacy of Glyburide can be decreased when used in combination with Hydrocortisone.	Approved
Glycerol Phenylbutyrate	The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Hydrocortisone.	Approved
Grepafloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Grepafloxacin.	Approved, Investigational, Withdrawn
Guacetisal	The risk or severity of adverse effects can be increased when Guacetisal is combined with Hydrocortisone.	Experimental
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydrocortisone.	Investigational
Hemoglobin crosfumaril	The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Hydrocortisone.	Experimental
Hepatitis A Vaccine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hepatitis A Vaccine.	Approved
Hepatitis B Vaccine (Recombinant)	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hepatitis B Vaccine (Recombinant).	Approved, Withdrawn
Hexestrol	The serum concentration of Hydrocortisone can be increased when it is combined with Hexestrol.	Withdrawn
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with Hydrocortisone.	Investigational
Human rabies virus immune globulin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Human rabies virus immune globulin.	Approved
Huperzine A	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Huperzine A.	Approved, Investigational
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Hydrochlorothiazide	Hydrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydroflumethiazide	Hydrocortisone may increase the hypokalemic activities of Hydroflumethiazide.	Approved, Investigational
Hydrotalcite	The bioavailability of Hydrocortisone can be decreased when combined with Hydrotalcite.	Approved, Experimental, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Hydrocortisone.	Approved
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Hydrocortisone.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with Hydrocortisone.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Hydrocortisone.	Approved, Investigational
Icosapent	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Icosapent.	Approved, Nutraceutical
Idelalisib	The metabolism of Hydrocortisone can be decreased when combined with Idelalisib.	Approved
Imatinib	The metabolism of Hydrocortisone can be decreased when combined with Imatinib.	Approved
Imidazole salicylate	The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Hydrocortisone.	Experimental
Indacaterol	Indacaterol may increase the hypokalemic activities of Hydrocortisone.	Approved
Indapamide	Hydrocortisone may increase the hypokalemic activities of Indapamide.	Approved
Indinavir	The metabolism of Hydrocortisone can be decreased when combined with Indinavir.	Approved
Indobufen	The risk or severity of adverse effects can be increased when Indobufen is combined with Hydrocortisone.	Investigational
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Hydrocortisone.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with Hydrocortisone.	Withdrawn
INGN 201	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with INGN 225.	Investigational
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Human	The therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrocortisone.	Approved
Ipidacrine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ipidacrine.	Experimental
Isavuconazole	The serum concentration of Hydrocortisone can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The metabolism of Hydrocortisone can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isoflurophate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Isoflurophate.	Approved, Investigational, Withdrawn
Isoniazid	The serum concentration of Isoniazid can be decreased when it is combined with Hydrocortisone.	Approved, Investigational
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with Hydrocortisone.	Withdrawn
Isradipine	The metabolism of Hydrocortisone can be decreased when combined with Isradipine.	Approved, Investigational
Itraconazole	The metabolism of Hydrocortisone can be decreased when combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Hydrocortisone can be increased when it is combined with Ivacaftor.	Approved
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).	Approved
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with Hydrocortisone.	Experimental
Ketoconazole	The metabolism of Hydrocortisone can be decreased when combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Hydrocortisone.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Hydrocortisone.	Approved
Lacidipine	The serum concentration of Lacidipine can be decreased when it is combined with Hydrocortisone.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Hydrocortisone.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Leflunomide.	Approved, Investigational
Levofloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin.	Approved, Investigational
Linagliptin	The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrocortisone.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydrocortisone.	Approved
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Hydrocortisone.	Investigational
Lisuride	The risk or severity of adverse effects can be increased when Lisuride is combined with Hydrocortisone.	Approved, Investigational
Lomefloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Lomefloxacin.	Approved, Investigational
Lonazolac	The risk or severity of adverse effects can be increased when Lonazolac is combined with Hydrocortisone.	Experimental
Lopinavir	The metabolism of Hydrocortisone can be decreased when combined with Lopinavir.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Hydrocortisone.	Approved, Investigational
Lorpiprazole	The serum concentration of Hydrocortisone can be increased when it is combined with Lorpiprazole.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Hydrocortisone.	Approved, Investigational
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with Hydrocortisone.	Approved, Investigational
Luliconazole	The serum concentration of Hydrocortisone can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Hydrocortisone can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Hydrocortisone.	Approved, Investigational
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Hydrocortisone.	Illicit, Investigational, Withdrawn
Magaldrate	The bioavailability of Hydrocortisone can be decreased when combined with Magaldrate.	Approved, Withdrawn
Magnesium carbonate	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium carbonate.	Approved, Investigational
Magnesium hydroxide	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium hydroxide.	Approved, Investigational
Magnesium oxide	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.	Approved
Magnesium peroxide	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium peroxide.	Experimental
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Hydrocortisone.	Approved
Magnesium silicate	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium silicate.	Approved
Magnesium Trisilicate	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium Trisilicate.	Approved
Malathion	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Malathion.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Hydrocortisone.	Approved, Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Hydrocortisone.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Hydrocortisone.	Approved
Mefloquine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mefloquine.	Approved, Investigational
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Hydrocortisone.	Approved, Vet Approved
Memantine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Memantine.	Approved, Investigational
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Hydrocortisone.	Approved
Mesterolone	Hydrocortisone may increase the fluid retaining activities of Mesterolone.	Experimental
Mestranol	The serum concentration of Hydrocortisone can be increased when it is combined with Mestranol.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Hydrocortisone.	Approved, Investigational, Withdrawn
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Hydrocortisone.	Experimental
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.	Approved
Methallenestril	The serum concentration of Hydrocortisone can be increased when it is combined with Methallenestril.	Experimental
Methanesulfonyl Fluoride	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Methanesulfonyl Fluoride.	Investigational
Methyclothiazide	Hydrocortisone may increase the hypokalemic activities of Methyclothiazide.	Approved
Methyl salicylate	The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone.	Approved, Vet Approved
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydrocortisone.	Approved
Methyltestosterone	Hydrocortisone may increase the fluid retaining activities of Methyltestosterone.	Approved
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Hydrocortisone.	Approved
Metoclopramide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Metoclopramide.	Approved, Investigational
Metolazone	Hydrocortisone may increase the hypokalemic activities of Metolazone.	Approved
Mevastatin	The serum concentration of Mevastatin can be increased when it is combined with Hydrocortisone.	Experimental
Mifamurtide	The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Hydrocortisone.	Approved, Experimental
Mifepristone	The therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Mifepristone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrocortisone.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Hydrocortisone.	Approved
Minaprine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Minaprine.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Mitotane	The serum concentration of Hydrocortisone can be decreased when it is combined with Mitotane.	Approved
Mivacurium	Mivacurium may increase the adverse neuromuscular activities of Hydrocortisone.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Hydrocortisone.	Investigational
Mofebutazone	The risk or severity of adverse effects can be increased when Mofebutazone is combined with Hydrocortisone.	Experimental
Morniflumate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Morniflumate.	Approved
Moxestrol	The serum concentration of Hydrocortisone can be increased when it is combined with Moxestrol.	Experimental
Moxifloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Hydrocortisone.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with Hydrocortisone.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Hydrocortisone.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Hydrocortisone.	Approved
Nalidixic Acid	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nalidixic Acid.	Approved, Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Hydrocortisone.	Approved
Nandrolone	Hydrocortisone may increase the fluid retaining activities of Nandrolone.	Experimental, Investigational
Nandrolone decanoate	Hydrocortisone may increase the fluid retaining activities of Nandrolone decanoate.	Approved, Illicit
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Hydrocortisone.	Approved, Vet Approved
Natalizumab	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab.	Approved, Investigational
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Nefazodone	The metabolism of Hydrocortisone can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Hydrocortisone can be decreased when combined with Nelfinavir.	Approved
Nemonoxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nemonoxacin.	Investigational
Neostigmine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Neostigmine.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Hydrocortisone.	Approved, Investigational
Netupitant	The serum concentration of Hydrocortisone can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The serum concentration of Hydrocortisone can be decreased when it is combined with Nevirapine.	Approved
Nicergoline	The risk or severity of adverse effects can be increased when Nicergoline is combined with Hydrocortisone.	Approved, Investigational
Nicorandil	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nicorandil.	Approved, Investigational
Nifenazone	The risk or severity of adverse effects can be increased when Nifenazone is combined with Hydrocortisone.	Experimental
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Hydrocortisone.	Approved
Nilotinib	The metabolism of Hydrocortisone can be decreased when combined with Nilotinib.	Approved, Investigational
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Hydrocortisone.	Approved, Investigational, Withdrawn
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Hydrocortisone.	Approved
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Hydrocortisone.	Investigational
Norfloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Norfloxacin.	Approved
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Hydrocortisone.	Approved, Investigational
Ofloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ofloxacin.	Approved
Olaparib	The metabolism of Hydrocortisone can be decreased when combined with Olaparib.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Hydrocortisone.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone.	Approved
Orgotein	The risk or severity of adverse effects can be increased when Orgotein is combined with Hydrocortisone.	Vet Approved
Osimertinib	The serum concentration of Hydrocortisone can be increased when it is combined with Osimertinib.	Approved
Oxandrolone	Hydrocortisone may increase the fluid retaining activities of Oxandrolone.	Approved, Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Hydrocortisone.	Approved
Oxolinic acid	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Oxolinic acid.	Experimental
Oxymetholone	Hydrocortisone may increase the fluid retaining activities of Oxymetholone.	Approved, Illicit
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Hydrocortisone.	Approved, Withdrawn
Palbociclib	The serum concentration of Hydrocortisone can be increased when it is combined with Palbociclib.	Approved, Investigational
Palmidrol	The risk or severity of adverse effects can be increased when Palmidrol is combined with Hydrocortisone.	Experimental, Nutraceutical
Paraoxon	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Paraoxon.	Experimental
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with Hydrocortisone.	Approved
Parthenolide	The risk or severity of adverse effects can be increased when Parthenolide is combined with Hydrocortisone.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Hydrocortisone.	Approved
Pazufloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pazufloxacin.	Investigational
Pefloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pefloxacin.	Approved
Pentobarbital	The serum concentration of Hydrocortisone can be decreased when it is combined with Pentobarbital.	Approved, Investigational, Vet Approved
Pergolide	The risk or severity of adverse effects can be increased when Pergolide is combined with Hydrocortisone.	Approved, Investigational, Vet Approved, Withdrawn
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Hydrocortisone.	Approved, Investigational, Withdrawn
Phenobarbital	The serum concentration of Hydrocortisone can be decreased when it is combined with Phenobarbital.	Approved, Investigational
Phenyl aminosalicylate	The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Hydrocortisone.	Approved
Phenylacetic acid	The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Hydrocortisone.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Hydrocortisone.	Approved, Vet Approved
Phenylbutyric acid	The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Phenytoin	The serum concentration of Hydrocortisone can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Physostigmine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Physostigmine.	Approved, Investigational
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydrocortisone.	Approved, Investigational
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Pipemidic acid	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pipemidic acid.	Experimental
Piretanide	Hydrocortisone may increase the hypokalemic activities of Piretanide.	Approved
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Hydrocortisone.	Approved, Investigational
Piromidic acid	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Piromidic acid.	Experimental
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Hydrocortisone.	Approved, Investigational
Pirprofen	The risk or severity of adverse effects can be increased when Pirprofen is combined with Hydrocortisone.	Experimental
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Hydrocortisone.	Approved
Pitolisant	The serum concentration of Hydrocortisone can be decreased when it is combined with Pitolisant.	Approved, Investigational
Polyestradiol phosphate	The serum concentration of Hydrocortisone can be increased when it is combined with Polyestradiol phosphate.	Approved
Polythiazide	Hydrocortisone may increase the hypokalemic activities of Polythiazide.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pomalidomide.	Approved
Posaconazole	The metabolism of Hydrocortisone can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Pranoprofen	The risk or severity of adverse effects can be increased when Pranoprofen is combined with Hydrocortisone.	Experimental, Investigational
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone.	Approved
Primidone	The serum concentration of Hydrocortisone can be decreased when it is combined with Primidone.	Approved, Vet Approved
Proglumetacin	The risk or severity of adverse effects can be increased when Proglumetacin is combined with Hydrocortisone.	Experimental
Promestriene	The serum concentration of Hydrocortisone can be increased when it is combined with Promestriene.	Investigational
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with Hydrocortisone.	Approved, Investigational
Propyphenazone	The risk or severity of adverse effects can be increased when Propyphenazone is combined with Hydrocortisone.	Experimental
Proquazone	The risk or severity of adverse effects can be increased when Proquazone is combined with Hydrocortisone.	Experimental
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Hydrocortisone.	Approved
Prulifloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Hydrocortisone.	Investigational
Pyridostigmine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pyridostigmine.	Approved, Investigational
Quinestrol	The serum concentration of Hydrocortisone can be increased when it is combined with Quinestrol.	Approved
Quinethazone	Hydrocortisone may increase the hypokalemic activities of Quinethazone.	Approved
Rabies virus inactivated antigen, A	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rabies virus inactivated antigen, A.	Approved, Investigational
Rabies virus inactivated antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Hydrocortisone.	Approved, Investigational
Rapacuronium	Rapacuronium may increase the adverse neuromuscular activities of Hydrocortisone.	Withdrawn
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Hydrocortisone.	Approved, Experimental, Investigational
Rifabutin	The serum concentration of Hydrocortisone can be decreased when it is combined with Rifabutin.	Approved, Investigational
Rifampicin	The serum concentration of Hydrocortisone can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Hydrocortisone can be decreased when it is combined with Rifapentine.	Approved, Investigational
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Hydrocortisone.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Hydrocortisone.	Approved
Rindopepimut	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rindopepimut.	Investigational
Rivastigmine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rivastigmine.	Approved, Investigational
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with Hydrocortisone.	Approved, Investigational, Withdrawn
Roflumilast	Roflumilast may increase the immunosuppressive activities of Hydrocortisone.	Approved
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Rosoxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin.	Approved, Investigational
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Hydrocortisone.	Approved
Rotavirus Vaccine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rotavirus Vaccine.	Approved
Rubella virus vaccine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rubella virus vaccine.	Approved, Investigational
Rucaparib	The metabolism of Hydrocortisone can be decreased when combined with Rucaparib.	Approved, Investigational
Rufloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rufloxacin.	Experimental
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Hydrocortisone.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Hydrocortisone.	Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigen	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Salmonella typhi ty2 vi polysaccharide antigen.	Approved
Salmonella typhi ty21a live antigen	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Salmonella typhi ty21a live antigen.	Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Hydrocortisone.	Approved
Saquinavir	The metabolism of Hydrocortisone can be decreased when combined with Saquinavir.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Sarilumab.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be decreased when it is combined with Hydrocortisone.	Approved
Secoisolariciresinol	The serum concentration of Hydrocortisone can be increased when it is combined with Secoisolariciresinol.	Investigational
Seliciclib	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Seliciclib.	Investigational
Semapimod	The risk or severity of adverse effects can be increased when Semapimod is combined with Hydrocortisone.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Seratrodast is combined with Hydrocortisone.	Approved
Serrapeptase	The risk or severity of adverse effects can be increased when Serrapeptase is combined with Hydrocortisone.	Investigational
Sildenafil	The metabolism of Hydrocortisone can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Hydrocortisone.	Approved
Siltuximab	The serum concentration of Hydrocortisone can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Hydrocortisone can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Hydrocortisone.	Approved
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Sitafloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sitafloxacin.	Experimental, Investigational
Sitagliptin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Sodium bicarbonate	The bioavailability of Hydrocortisone can be decreased when combined with Sodium bicarbonate.	Approved
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Hydrocortisone.	Investigational
Sparfloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sparfloxacin.	Approved, Investigational
SRP 299	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with SRP 299.	Investigational
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Hydrocortisone.	Investigational
St. John's Wort	The serum concentration of Hydrocortisone can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stanolone	Hydrocortisone may increase the fluid retaining activities of Stanolone.	Illicit, Investigational
Stanozolol	Hydrocortisone may increase the fluid retaining activities of Stanozolol.	Approved, Vet Approved
Stiripentol	The serum concentration of Hydrocortisone can be increased when it is combined with Stiripentol.	Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone.	Approved
Sulfisoxazole	The metabolism of Hydrocortisone can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Hydrocortisone.	Approved, Investigational
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Hydrocortisone.	Approved, Withdrawn
Suxibuzone	The risk or severity of adverse effects can be increased when Suxibuzone is combined with Hydrocortisone.	Experimental
Synthetic Conjugated Estrogens, A	The serum concentration of Hydrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, A.	Approved
Synthetic Conjugated Estrogens, B	The serum concentration of Hydrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.	Approved
Tacrine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tacrine.	Investigational, Withdrawn
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Hydrocortisone.	Approved, Investigational
Talniflumate	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Talniflumate.	Approved
Tarenflurbil	The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Hydrocortisone.	Investigational
Tecemotide	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tecemotide.	Investigational
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with Hydrocortisone.	Approved, Withdrawn
Telithromycin	The metabolism of Hydrocortisone can be decreased when combined with Telithromycin.	Approved
Temafloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Temafloxacin.	Withdrawn
Tenidap	The risk or severity of adverse effects can be increased when Tenidap is combined with Hydrocortisone.	Experimental
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Hydrocortisone.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Tepoxalin is combined with Hydrocortisone.	Vet Approved
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Hydrocortisone.	Experimental
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Hydrocortisone.	Approved
Testosterone	Hydrocortisone may increase the fluid retaining activities of Testosterone.	Approved, Investigational
Testosterone cypionate	The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Hydrocortisone.	Approved
Testosterone enanthate	The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Hydrocortisone.	Approved
Testosterone propionate	Hydrocortisone may increase the fluid retaining activities of Testosterone propionate.	Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoate	The risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Hydrocortisone.	Approved, Investigational
TG4010	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with TG4010.	Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Hydrocortisone.	Approved
Tibolone	The serum concentration of Hydrocortisone can be increased when it is combined with Tibolone.	Approved, Investigational
Ticlopidine	The metabolism of Hydrocortisone can be decreased when combined with Ticlopidine.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with Hydrocortisone.	Investigational
Tocilizumab	The serum concentration of Hydrocortisone can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	Hydrocortisone may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Hydrocortisone.	Approved, Investigational
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Hydrocortisone.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Hydrocortisone.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Hydrocortisone.	Approved, Investigational
Torasemide	Hydrocortisone may increase the hypokalemic activities of Torasemide.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with Hydrocortisone.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the neutropenic activities of Hydrocortisone.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Triamcinolone.	Approved, Vet Approved
Tribenoside	The risk or severity of adverse effects can be increased when Tribenoside is combined with Hydrocortisone.	Experimental
Trichlorfon	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trichlorfon.	Vet Approved
Trichlormethiazide	Hydrocortisone may increase the hypokalemic activities of Trichlormethiazide.	Approved, Vet Approved
Triptolide	The risk or severity of adverse effects can be increased when Triptolide is combined with Hydrocortisone.	Investigational
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydrocortisone.	Investigational, Withdrawn
Trolamine salicylate	The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone.	Approved
Tromethamine	The bioavailability of Hydrocortisone can be decreased when combined with Tromethamine.	Approved
Trovafloxacin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trovafloxacin.	Approved, Investigational, Withdrawn
Tubocurarine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tubocurarine.	Approved
Typhoid Vaccine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Typhoid Vaccine.	Approved
Tyrothricin	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tyrothricin.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with Hydrocortisone.	Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Varicella Zoster Vaccine (Live/Attenuated).	Approved
Vemurafenib	The serum concentration of Hydrocortisone can be increased when it is combined with Vemurafenib.	Approved
Venlafaxine	The metabolism of Hydrocortisone can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Hydrocortisone can be decreased when combined with Verapamil.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Vincristine	The excretion of Vincristine can be decreased when combined with Hydrocortisone.	Approved, Investigational
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Hydrocortisone.	Approved, Investigational
Voriconazole	The metabolism of Hydrocortisone can be decreased when combined with Voriconazole.	Approved, Investigational
Warfarin	Hydrocortisone may increase the anticoagulant activities of Warfarin.	Approved
Yellow Fever Vaccine	The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Yellow Fever Vaccine.	Approved, Investigational
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Hydrocortisone.	Approved, Investigational
Zeranol	The serum concentration of Hydrocortisone can be increased when it is combined with Zeranol.	Vet Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Hydrocortisone.	Approved, Investigational, Withdrawn
Ziprasidone	The metabolism of Hydrocortisone can be decreased when combined with Ziprasidone.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Hydrocortisone.	Withdrawn

Food Interactions

• Take with food to reduce irritation. Calcium, phosphorous, potassium, Vitamin A, C, D and zinc needs increased with long term use.

References

Synthesis Reference

Manfred Baumgarth, Dieter Orth, Jurgen Harting, Hans Schaefer, Achim Zesch, "Hydrocortisone orthoesters, pharmaceutical formulations thereof and processes for the preparation thereof." U.S. Patent US4264584, issued March, 1974.

US4264584

General References

1. de Weerth C, Zijl RH, Buitelaar JK: Development of cortisol circadian rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52. [PubMed:12932892]
2. Palacios R, Sugawara I: Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol. 1982 Jan;15(1):25-31. [PubMed:6461917]
3. KNIGHT RP Jr, KORNFELD DS, GLASER GH, BONDY PK: Effects of intravenous hydrocortisone on electrolytes of serum and urine in man. J Clin Endocrinol Metab. 1955 Feb;15(2):176-81. [PubMed:13233328]

External Links

Human Metabolome Database

HMDB0000063

KEGG Drug

D00088

KEGG Compound

C00735

PubChem Compound

5754

PubChem Substance

46505089

ChemSpider

5551

BindingDB

13775

ChEBI

17650

ChEMBL

CHEMBL389621

Therapeutic Targets Database

DAP000718

PharmGKB

PA449905

IUPHAR

2868

Guide to Pharmacology

GtP Drug Page

HET

HCY

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Hydrocortisone

ATC Codes

S02BA01 — Hydrocortisone

• S02BA — Corticosteroids
• S02B — CORTICOSTEROIDS
• S02 — OTOLOGICALS
• S — SENSORY ORGANS

S01CA03 — Hydrocortisone and antiinfectives

• S01CA — Corticosteroids and antiinfectives in combination
• S01C — ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
• S01 — OPHTHALMOLOGICALS
• S — SENSORY ORGANS

S01CB03 — Hydrocortisone

• S01CB — Corticosteroids/antiinfectives/mydriatics in combination
• S01C — ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
• S01 — OPHTHALMOLOGICALS
• S — SENSORY ORGANS

S03CA04 — Hydrocortisone and antiinfectives

• S03CA — Corticosteroids and antiinfectives in combination
• S03C — CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
• S03 — OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
• S — SENSORY ORGANS

D07AA02 — Hydrocortisone

• D07AA — Corticosteroids, weak (group I)
• D07A — CORTICOSTEROIDS, PLAIN
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

D07BB04 — Hydrocortisone butyrate and antiseptics

• D07BB — Corticosteroids, moderately potent, combinations with antiseptics
• D07B — CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

C05AA01 — Hydrocortisone

• C05AA — Corticosteroids
• C05A — AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
• C05 — VASOPROTECTIVES
• C — CARDIOVASCULAR SYSTEM

D07AB02 — Hydrocortisone butyrate

• D07AB — Corticosteroids, moderately potent (group II)
• D07A — CORTICOSTEROIDS, PLAIN
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

S02CA03 — Hydrocortisone and antiinfectives

• S02CA — Corticosteroids and antiinfectives in combination
• S02C — CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
• S02 — OTOLOGICALS
• S — SENSORY ORGANS

D07AC16 — Hydrocortisone aceponate

• D07AC — Corticosteroids, potent (group III)
• D07A — CORTICOSTEROIDS, PLAIN
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

A01AC03 — Hydrocortisone

• A01AC — Corticosteroids for local oral treatment
• A01A — STOMATOLOGICAL PREPARATIONS
• A01 — STOMATOLOGICAL PREPARATIONS
• A — ALIMENTARY TRACT AND METABOLISM

D07BA04 — Hydrocortisone and antiseptics

• D07BA — Corticosteroids, weak, combinations with antiseptics
• D07B — CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

D07CA01 — Hydrocortisone and antibiotics

• D07CA — Corticosteroids, weak, combinations with antibiotics
• D07C — CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

S01BA02 — Hydrocortisone

• S01BA — Corticosteroids, plain
• S01B — ANTIINFLAMMATORY AGENTS
• S01 — OPHTHALMOLOGICALS
• S — SENSORY ORGANS

S01BB01 — Hydrocortisone and mydriatics

• S01BB — Corticosteroids and mydriatics in combination
• S01B — ANTIINFLAMMATORY AGENTS
• S01 — OPHTHALMOLOGICALS
• S — SENSORY ORGANS

R01AD60 — Hydrocortisone, combinations

• R01AD — Corticosteroids
• R01A — DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
• R01 — NASAL PREPARATIONS
• R — RESPIRATORY SYSTEM

A07EA02 — Hydrocortisone

• A07EA — Corticosteroids acting locally
• A07E — INTESTINAL ANTIINFLAMMATORY AGENTS
• A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
• A — ALIMENTARY TRACT AND METABOLISM

H02AB09 — Hydrocortisone

• H02AB — Glucocorticoids
• H02A — CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
• H02 — CORTICOSTEROIDS FOR SYSTEMIC USE
• H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

D07XA01 — Hydrocortisone

• D07XA — Corticosteroids, weak, other combinations
• D07X — CORTICOSTEROIDS, OTHER COMBINATIONS
• D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

AHFS Codes

• 68:04.00 — Adrenals
• 84:06.00 — Anti-inflammatory Agents
• 56:36.00 — Anti-inflammatory Agents

PDB Entries

2v95 / 2vdy / 4c49 / 4p6x / 5hgc

FDA label

Download (30 KB)

MSDS

Download (73.6 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Active Not Recruiting	Other	Insulin Resistance	1
0	Completed	Treatment	Fibromyalgia	1
0	Not Yet Recruiting	Basic Science	BMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome	2
0	Recruiting	Basic Science	Depression	1
0	Recruiting	Basic Science	Healthy Volunteers	1
0	Recruiting	Basic Science	Human Immunodeficiency Virus (HIV)	1
1	Active Not Recruiting	Basic Science	BMI >30 kg/m2	1
1	Active Not Recruiting	Treatment	Rotator Cuff Tear - Partial Thickness	1
1	Completed	Not Available	Infection NOS	1
1	Completed	Not Available	Relative Adrenal Insufficiency / Sepsis	1
1	Completed	Basic Science	Healthy Volunteers	2
1	Completed	Basic Science	Healthy Volunteers / Inflammatory Reaction / Pain	1
1	Completed	Other	Adrenal Insufficiency	1
1	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndromes (MDS)	1
1	Completed	Treatment	Adrenal Insufficiency	1
1	Completed	Treatment	Adrenal Insufficiency / Congenital Adrenal Hyperplasia (CAH)	1
1	Completed	Treatment	Arterial Hypotension / Blood Pressures / Infant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants	1
1	Completed	Treatment	Erythemas / Pain	1
1	Completed	Treatment	Healthy Volunteers	1
1	Completed	Treatment	Knee Osteoarthritis (Knee OA)	1
1	Completed	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1	Completed	Treatment	Psoriasis Vulgaris	1
1	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
1	Recruiting	Treatment	Acute Lymphoblastic Leukemia With Failed Remission / Acute Lymphoblastic Leukemia, in Relapse	1
1	Recruiting	Treatment	Adrenal Insufficiency	1
1	Recruiting	Treatment	Heroin Dependence / Opioid Use Disorders	1
1	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
1	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1	Recruiting	Treatment	Lymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)	1
1	Unknown Status	Treatment	Ovarian Epithelial Cancer	1
1	Withdrawn	Basic Science	Diabetes, Diabetes Mellitus Type 1	1
1, 2	Completed	Diagnostic	Systemic Lupus Erythematosus (SLE)	1
1, 2	Completed	Treatment	21-Hydroxylase Deficiency / Adrenogenital Syndrome / Congenital Adrenal Hyperplasia (CAH)	1
1, 2	Completed	Treatment	Cardiac Arrest	1
1, 2	Completed	Treatment	Recurrent Childhood Acute Lymphoblastic Leukemia	1
1, 2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
1, 2	Recruiting	Treatment	Addison's Disease / Adrenal Hyperplasia Congenital	1
1, 2	Recruiting	Treatment	Adult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma	1
1, 2	Recruiting	Treatment	Inhospital Cardiac Arrest	1
1, 2	Terminated	Basic Science	Renin Angiotensin	1
1, 2	Terminated	Treatment	Adenocarcinoma, Prostate / Recurrent Prostate Carcinoma / Stage III Prostate Cancer / Stage IV Prostate Cancer	1
1, 2	Terminated	Treatment	Anaplastic Large Cell Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma	1
1, 2	Terminated	Treatment	Prostate Cancer	1
2	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	2
2	Active Not Recruiting	Treatment	Lymphoma, Lymphoblastic	1
2	Active Not Recruiting	Treatment	Prostate Cancer	1
2	Completed	Not Available	Postoperative Complications / Postoperative Pancreatitis	1
2	Completed	Prevention	Chronic Lung Disease of Prematurity	1
2	Completed	Prevention	Chronic Lung Disease of Prematurity / Encephalomalacia / Premature Births	1
2	Completed	Supportive Care	Advanced Malignant Neoplasm / Dermatologic Complication / Dermatologic Complications / Neoplasms, Malignant	1
2	Completed	Treatment	Acute Lymphocytic Leukemia (ALL)	1
2	Completed	Treatment	Acute Respiratory Distress Syndrome (ARDS) / Multiple Organ Failure	1
2	Completed	Treatment	Adenocarcinoma, Prostate / Prostate Cancer	1
2	Completed	Treatment	Adrenal Hyperplasia, Congenital	1
2	Completed	Treatment	Adrenal Insufficiency / Congenital Adrenal Hyperplasia (CAH) / Excess Androgen	1
2	Completed	Treatment	Angioedema	1
2	Completed	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Blood Cancers / CLL / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome	1
2	Completed	Treatment	Blood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous	1
2	Completed	Treatment	Cardiac Output, Low	1
2	Completed	Treatment	Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Hemorrhoids	1
2	Completed	Treatment	Jet Lag Syndrome	1
2	Completed	Treatment	Leukemia, Mast-Cell / Mantle Cell Lymphoma (MCL)	1
2	Completed	Treatment	Leukemias	1
2	Completed	Treatment	Lymphohistiocytosis, Hemophagocytic	1
2	Completed	Treatment	Opioid Dependence	1
2	Completed	Treatment	Paediatric Sepsis / Pediatric Sepsis / Sepsis	1
2	Completed	Treatment	Prostate Cancer	1
2	Completed	Treatment	Prurigo Nodularis	1
2	Completed	Treatment	Rash	1
2	Completed	Treatment	Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia	1
2	Not Yet Recruiting	Basic Science	Adolescent Development / Borderline Personality Disorder (BPD)	1
2	Not Yet Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)	1
2	Not Yet Recruiting	Treatment	Congenital Adrenal Hyperplasia (CAH)	1
2	Recruiting	Treatment	Acute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)	1
2	Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma	1
2	Recruiting	Treatment	Adrenal Hyperplasia, Congenital	1
2	Recruiting	Treatment	Apomorphine-induced Skin Reactions / Parkinson's Disease (PD)	1
2	Recruiting	Treatment	Colorectal Cancers / Head and Neck Carcinoma	1
2	Recruiting	Treatment	Critically Ill / Sepsis / Shock, Septic / Vasoplegic Syndrome	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes	1
2	Recruiting	Treatment	Prostate Cancer	1
2	Recruiting	Treatment	Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma	1
2	Recruiting	Treatment	Sepsis, Severe / Shock, Septic	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic	1
2	Terminated	Treatment	Acute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia	1
2	Terminated	Treatment	Blood and Marrow Transplant (BMT) / Diffuse Large B-Cell / Lymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphomas: Non-Hodgkin / Malignant Lymphoma, Non-Hodgkin / Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
2	Terminated	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)	1
2	Terminated	Treatment	Phobic Disorders	1
2	Unknown Status	Treatment	Addison's Disease	1
2	Unknown Status	Treatment	Cirrhosis With Ascites	1
2	Unknown Status	Treatment	Injuries, Whiplash	1
2	Unknown Status	Treatment	Leukemias	1
2	Unknown Status	Treatment	Lymphoblastic Leukemia, Acute	1
2, 3	Active Not Recruiting	Treatment	Asphyxia / Hypoxic-Ischaemic Encephalopathy	1
2, 3	Active Not Recruiting	Treatment	Childhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma	1
2, 3	Completed	Prevention	Injuries, Multiple	1
2, 3	Completed	Treatment	Addison's Disease	1
2, 3	Completed	Treatment	Adrenal Insufficiency	1
2, 3	Completed	Treatment	Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
2, 3	Recruiting	Treatment	Left Ventricular Remodeling / ST Segment Elevation Myocardial Infarction (STEMI)	1
2, 3	Unknown Status	Treatment	Mortality / Ventilations, Mechanical	1
3	Active Not Recruiting	Treatment	Acute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Active Not Recruiting	Treatment	Cardiovascular Insufficiency / Infant, Newborn, Diseases	1
3	Completed	Supportive Care	Cardiac Toxicity / Leukemias / Malignant Lymphomas	1
3	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
3	Completed	Treatment	Alcohol Craving / Stress, Physiological / Stress, Psychological	1
3	Completed	Treatment	Alopecia Areata (AA)	1
3	Completed	Treatment	Cardiac Arrest	1
3	Completed	Treatment	Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	1
3	Completed	Treatment	Chronic Lung Disease of Prematurity	1
3	Completed	Treatment	Coagulation Dysfunction in Septic Shock / Hemodynamic Improvement Induced by Hydrocortisone	1
3	Completed	Treatment	Healthy Volunteers	1
3	Completed	Treatment	Herpes Labialis	1
3	Completed	Treatment	Leukemias / Malignant Lymphomas	1
3	Completed	Treatment	Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
3	Completed	Treatment	Neonatal Hypotension	1
3	Completed	Treatment	Oral Submucous Fibrosis	1
3	Completed	Treatment	Otitis Externa	1
3	Completed	Treatment	Patient Admitted in Reanimation	1
3	Completed	Treatment	Prostate Cancer	1
3	Completed	Treatment	Psoriasis Vulgaris	1
3	Completed	Treatment	Sepsis / Shock, Septic	1
3	Completed	Treatment	Severe Sepsis	1
3	Completed	Treatment	Shock, Septic	3
3	Not Yet Recruiting	Supportive Care	Sepsis	1
3	Not Yet Recruiting	Treatment	Congenital Adrenal Hyperplasia (CAH)	1
3	Not Yet Recruiting	Treatment	Immune Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic	1
3	Recruiting	Prevention	Chronic Lung Disease of Prematurity / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Very Low Birth Weight Infant	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukemia, Pediatric	1
3	Recruiting	Treatment	B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	B Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia	1
3	Recruiting	Treatment	Community Acquired Pneumonia (CAP)	1
3	Recruiting	Treatment	Congenital Adrenal Hyperplasia (CAH)	2
3	Recruiting	Treatment	Liver Cirrhosis	1
3	Recruiting	Treatment	Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit	1
3	Suspended	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Terminated	Treatment	Evidence of Liver Transplantation / Transplantations	1
3	Terminated	Treatment	Influenza in Humans / Viral Pneumonia	1
3	Terminated	Treatment	Prostatic Neoplasms	1
3	Unknown Status	Treatment	Low Back Pain (LBP)	1
4	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
4	Completed	Not Available	Minor burns	1
4	Completed	Basic Science	Feeling Anxious	1
4	Completed	Basic Science	Healthy Volunteers	1
4	Completed	Basic Science	Stress Disorders, Posttraumatic	1
4	Completed	Prevention	Postoperative Inflammatory Response	1
4	Completed	Prevention	Posttraumatic Stress Disorders / Systemic Inflammatory Response Syndrome (SIRS)	1
4	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
4	Completed	Treatment	Adrenal Insufficiency	1
4	Completed	Treatment	Asthma Bronchial	1
4	Completed	Treatment	Atopic Dermatitis (AD)	1
4	Completed	Treatment	Atopic Dermatitis (AD) / Psoriasis	1
4	Completed	Treatment	Coronary Artery Disease / Mitral Valve Regurgitation	1
4	Completed	Treatment	Hip Injuries	1
4	Completed	Treatment	Hyperglycemias	1
4	Completed	Treatment	Knee Replacement Surgery	1
4	Completed	Treatment	Rheumatic Diseases	1
4	Completed	Treatment	Shock	1
4	Completed	Treatment	Shock, Septic	1
4	Completed	Treatment	Snake Bites	1
4	Enrolling by Invitation	Treatment	Adrenal Insufficiency	1
4	Enrolling by Invitation	Treatment	Granuloma / Tracheostomy care	1
4	Not Yet Recruiting	Treatment	Ulcerative Colitis (UC)	1
4	Recruiting	Prevention	Neoplasms, Pancreatic / Pancreatic Fistula	1
4	Recruiting	Supportive Care	Rheumatoid Arthritis	1
4	Recruiting	Treatment	Atopic Dermatitis (AD)	1
4	Recruiting	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Recruiting	Treatment	Community Acquired Pneumonia (CAP)	1
4	Recruiting	Treatment	Critical Illness / Fluid Overload / Sepsis / Shock, Septic	1
4	Recruiting	Treatment	Function of Renal Transplant	1
4	Recruiting	Treatment	Granulomatous Mastitis	1
4	Recruiting	Treatment	Ulcerative Colitis (UC)	1
4	Terminated	Not Available	Asthma Bronchial	1
4	Terminated	Treatment	Partial Corticotrope Insufficiency	1
4	Terminated	Treatment	Shock, Septic	1
4	Unknown Status	Treatment	Acute Respiratory Distress Syndrome (ARDS) / Adrenal Insufficiency	1
4	Unknown Status	Treatment	Crohn's Disease (CD)	1
4	Unknown Status	Treatment	Pituitary Neoplasms / Postsurgical craniopharyngioma	1
4	Withdrawn	Treatment	Adrenal Insufficiency / Sepsis	1
4	Withdrawn	Treatment	Atopic Dermatitis (AD)	1
4	Withdrawn	Treatment	Phimosis	1
4	Withdrawn	Treatment	Post-Traumatic Stress Disorder (PTSD)	1
Not Available	Active Not Recruiting	Prevention	Dialysis Hypotension	1
Not Available	Active Not Recruiting	Supportive Care	Sjögren's Syndrome	1
Not Available	Completed	Not Available	Anxiety Disorders / Major Depressive Disorder (MDD)	1
Not Available	Completed	Not Available	Dependence, Cocaine	1
Not Available	Completed	Not Available	Heroin Dependence / Learning and Memory	1
Not Available	Completed	Not Available	Knee Osteoarthritis (Knee OA)	1
Not Available	Completed	Not Available	Sepsis	1
Not Available	Completed	Basic Science	Intrusive Memories	1
Not Available	Completed	Basic Science	Posttraumatic Stress Disorders	1
Not Available	Completed	Prevention	Fevers / Hemodynamics Instability / Hypothermia / Idiopathic orthostatic hypotension	1
Not Available	Completed	Screening	Other Diseases or Conditions	1
Not Available	Completed	Treatment	Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Severe Sepsis / Shock, Septic	1
Not Available	Completed	Treatment	Addison's Disease	1
Not Available	Completed	Treatment	Addison's Disease / BMI >30 kg/m2	1
Not Available	Completed	Treatment	Adrenal Hyperplasia, Congenital	1
Not Available	Completed	Treatment	Atopic Dermatitis (AD)	1
Not Available	Completed	Treatment	Heart Arrest	1
Not Available	Completed	Treatment	Heart Disease Congenital Complex	1
Not Available	Completed	Treatment	PTSD	1
Not Available	Completed	Treatment	Phobic Disorders	1
Not Available	Completed	Treatment	Pituitary Adenomas / Pituitary Diseases	1
Not Available	Completed	Treatment	Total Hip Replacement	1
Not Available	Recruiting	Basic Science	Borderline Personality Disorder (BPD) / PTSD	1
Not Available	Recruiting	Prevention	Post Traumatic Stress Disorder (PTSD)	1
Not Available	Recruiting	Treatment	Atopic Dermatitis (AD)	1
Not Available	Recruiting	Treatment	Fatty Acids, Nonesterified / Hydrocortisone / Hypopituitarism / Insulin Sensitivity / Lipids	1
Not Available	Recruiting	Treatment	Intussusception	1
Not Available	Recruiting	Treatment	Plantar fascial fibromatosis	1
Not Available	Recruiting	Treatment	Shock, Septic	1
Not Available	Suspended	Not Available	Some Studies Shows That the Steroid Can Reduce the Injury of the I/R of the Liver	1
Not Available	Terminated	Not Available	Nonvalvular Atrial Fibrillation	1
Not Available	Terminated	Prevention	Brain Death	1
Not Available	Terminated	Treatment	Necrotizing Enterocolitis	1
Not Available	Terminated	Treatment	Posttraumatic Stress Disorders	1
Not Available	Unknown Status	Prevention	Posttraumatic Stress Disorders	1
Not Available	Unknown Status	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
Not Available	Unknown Status	Treatment	Major Depressive Disorder (MDD)	1
Not Available	Unknown Status	Treatment	PTSD	1
Not Available	Withdrawn	Treatment	Post-Traumatic Stress Disorder (PTSD)	1

Pharmacoeconomics

Manufacturers

• Hi tech pharmacal co inc
• Allergan herbert div allergan inc
• Del ray laboratories inc
• Salix pharmaceuticals inc
• Bayer pharmaceuticals corp
• Monarch pharmaceuticals inc
• Valeant pharmaceuticals international
• Westwood squibb pharmaceuticals inc
• C and m pharmacal inc
• Pharmaceutical assoc inc div beach products
• Actavis mid atlantic llc
• Alpharma us pharmaceuticals division
• Altana inc
• Ambix laboratories div organics corp america
• Everylife
• E fougera div altana inc
• G and w laboratories inc
• Ingram pharmaceutical co
• Ivax pharmaceuticals inc
• Naska pharmacal co inc div rugby darby group cosmetics
• Perrigo new york inc
• Pharmaderm div altana inc
• Pharmafair inc
• Stiefel laboratories inc
• Syosset laboratories inc
• Taro pharmaceuticals usa inc
• Teva pharmaceuticals usa inc
• Topiderm inc
• Usl pharma inc
• Vintage pharmaceuticals inc
• Whiteworth towne paulsen inc
• Sanofi aventis us llc
• Coria laboratories ltd
• Medicis pharmaceutical corp
• Paddock laboratories inc
• Ani pharmaceuticals inc
• Teva pharmaceuticals usa
• Healthpoint ltd
• Allergan herbert skin care div allergan inc
• Pharmacia and upjohn co
• Baker norton pharmaceuticals inc
• Solvay pharmaceuticals
• Beta dermaceuticals inc
• Bluline laboratories inc
• Heran pharmaceutical inc
• Mericon industries inc
• Perrigo co
• Pfizer global research development
• Carolina medical products co
• Dermik laboratories div aventis pharmaceuticals inc
• Torch laboratories inc
• X gen pharmaceuticals inc
• Jsj pharmaceuticals llc
• Pfizer laboratories div pfizer inc
• Barr laboratories inc
• Elkins sinn div ah robins co inc
• John j ferrante
• Impax laboratories inc
• Inwood laboratories inc sub forest laboratories inc
• Lannett co inc
• Nexgen pharma inc
• Panray corp sub ormont drug and chemical co inc
• Parke davis div warner lambert co
• Purepac pharmaceutical co
• Roxane laboratories inc
• Sandoz inc
• Stiefel a gsk co
• Vintage pharmaceuticals llc
• Watson laboratories inc
• West ward pharmaceutical corp
• Merck and co inc
• Pfipharmecs div pfizer inc
• Schwarz pharma inc
• Able laboratories inc
• Hr cenci laboratories inc
• Ferndale laboratories inc
• Akorn inc
• Bel mar laboratories inc
• Colgate oral pharmaceuticals inc
• Taro pharmaceutical industries ltd
• Triax pharmaceuticals llc
• Yamanouchi europe bv
• Savage laboratories inc div altana inc
• Abbott laboratories pharmaceutical products div
• Abbott laboratories hosp products div
• Hospira inc
• Abraxis pharmaceutical products
• Baxter healthcare corp anesthesia and critical care
• International medication systems ltd
• Taro pharmaceuticals inc
• Ranbaxy laboratories inc

Packagers

• Actavis Group
• Advanced Pharmaceutical Services Inc.
• AG Marin Pharmaceuticals
• Alaven Pharmaceutical
• Alcon Laboratories
• Amerisource Health Services Corp.
• Ani Pharmaceuticals
• Anip Acquisition Co.
• Arbor Pharmaceuticals Incorporated
• A-S Medication Solutions LLC
• Avidas Pharmaceuticals
• Bay Pharma Inc.
• Bayer Healthcare
• Bergen Brunswig
• Beta Dermaceuticals
• Bio Pharm Inc.
• Bristol-Myers Squibb Co.
• C.O. Truxton Inc.
• Cardinal Health
• Carlisle Laboratories Inc.
• Carolina Medical Products Co.
• Chattem Chemicals Inc.
• Co Med Pharmaceuticals Inc.
• Colgate Oral
• Combe Inc.
• Consolidated Midland Corp.
• Contract Pharm
• Crown Laboratories Inc.
• Cutis Pharma Inc.
• Cypress Pharmaceutical Inc.
• Darby Dental Supply Co. Inc.
• Del Ray Dermatology
• Dermik Labs
• DispenseXpress Inc.
• Dispensing Solutions
• Diversified Healthcare Services Inc.
• Dofs Laboratories
• DPT Laboratories Ltd.
• DSC Laboratories
• E. Fougera and Co.
• ECR Pharmaceuticals
• Elkins-Sinn Inc.
• Enterprises Importfab Inc.
• Ferndale Labs
• G & W Labs
• Genesis Pharmaceutical Inc.
• Gertz
• H and H Laboratories
• H.J. Harkins Co. Inc.
• Harmony Laboratories Inc.
• Hi Tech Pharmacal Co. Inc.
• Hospira Inc.
• Inyx Usa Ltd.
• JHP Pharmaceuticals LLC
• Johnson & Johnson Healthcare
• JSJ Pharmaceuticals Inc.
• Kaiser Foundation Hospital
• Keltman Pharmaceuticals Inc.
• Lake Erie Medical and Surgical Supply
• Lehigh Valley Technologies Inc.
• Lyne Laboratories Inc.
• Major Pharmaceuticals
• Mallinckrodt Inc.
• Martin Surgical Supply
• Meda AB
• Mikart Inc.
• Murfreesboro Pharmaceutical Nursing Supply
• National Vitamin Company
• Nexgen Pharma Inc.
• Nycomed Inc.
• Paddock Labs
• Palmetto Pharmaceuticals Inc.
• Patheon Inc.
• Perrigo Co.
• Person & Covey
• Pfizer Inc.
• Pharmacia Inc.
• Pharmaderm
• Pharmedix
• Physician Partners Ltd.
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Professional Co.
• Prometic Pharma Inc.
• Qualitest
• Ranbaxy Laboratories
• Rebel Distributors Corp.
• Redpharm Drug
• Resource Optimization and Innovation LLC
• Rising Pharmaceuticals
• River's Edge Pharmaceuticals
• Rouses Point Pharmaceuticals LLC
• Salix Pharmaceuticals
• Sandhills Packaging Inc.
• Sandoz
• Sanofi-Aventis Inc.
• Schwarz Pharma Inc.
• Solvay Pharmaceuticals
• Southwood Pharmaceuticals
• Stanley Pharmaceuticals Ltd.
• Stat Rx Usa
• Stat Scripts LLC
• Summers Labs
• Suppositoria Laboratories Inc.
• Taro Pharmaceuticals USA
• Teva Pharmaceutical Industries Ltd.
• Topiderm Inc.
• Triax Pharmaceuticals LLC
• UCB Pharma
• United Pharmaceuticals
• United Research Laboratories Inc.
• Universal Laboratories Inc.
• Upsher Smith Laboratories
• Veratex Corp.
• Vertical Pharmaceuticals Inc.
• Vintage Pharmaceuticals Inc.
• West-Ward Pharmaceuticals
• Wockhardt Ltd.
• WraSer Pharmaceuticals
• Wyeth Pharmaceuticals

Dosage forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	100 mg/2mL
Powder	Topical
Powder, for solution	Topical
Soap	Topical	1 g/100g
Lotion	Topical	20 mg/mL
Cream	Topical	1 %
Kit
Suppository	Rectal
Ointment	Rectal; Topical
Cream	Topical	5 mg/g
Solution	Topical	1 g/100g
Ointment	Topical	1.02 g/100g
Cream; jelly	Topical	1 %
Lotion	Topical	.088 mL/88mL
Cream	Topical	.01 g/g
Cream	Topical	.284 g/28.4g
Cream	Topical	1 g/g
Cream	Topical	10 mg/g
Suspension	Auricular (otic)
Spray	Topical	1 g/100g
Cream	Topical	0.5 %
Spray	Topical	10 g/mL
Ointment	Ophthalmic	2.5 %
Ointment	Topical	10 mg
Tablet	Oral	10 mg
Tablet	Oral	20 mg
Enema	Rectal	100 mg
Enema; suspension	Rectal	100 mg
Ointment	Topical	100 g/g
Cream	Topical	1 mg
Aerosol, foam	Rectal	10 %
Aerosol, foam	Rectal	1500 mg/15g
Aerosol, foam	Topical	1500 mg/15g
Suppository	Rectal	10 mg
Suppository	Rectal	40 mg
Suspension	Topical
Ointment	Topical	10 mg/g
Gel	Topical	10 mg/g
Liquid	Topical	10 mg/mL
Lotion	Topical	1 g/100g
Lotion	Topical	10 mg/g
Gel	Topical	1 mg/g
Lotion	Topical	1 mg/mL
Lotion	Topical	1.18 mL/118mL
Kit	Topical
Lotion	Topical	.75 g/100mL
Cream	Topical	.284 g/287.4g
Cream	Topical	1 g/100mL
Cream	Topical	2.5 %
Solution	Topical	2.5 %
Kit	Oral
Ointment	Topical	10 mg/mL
Ointment	Topical	1 mL/100mL
Lotion	Topical	1 g/mL
Suppository	Rectal	.025 g/2g
Suppository	Rectal	25 mg/2g
Lotion / shampoo	Topical	5 mg/mL
Shampoo	Topical	5 mg/mL
Aerosol, spray	Topical	1.13 g/113g
Cream	Topical	1 h/100g
Cream	Topical	10 mg/mL
Cream	Topical	25 mg/g
Enema	Rectal	100 mg/60mL
Gel	Topical	1 g/100g
Lotion	Topical	25 mg/mL
Ointment	Topical	25 mg/1
Ointment	Topical	25 mg/g
Ointment	Topical	5 mg/g
Shampoo	Topical	1 g/100mL
Suspension	Rectal	100 mg/60mL
Tablet	Oral	10 mg/1
Tablet	Oral	20 mg/1
Tablet	Oral	5 mg/1
Ointment	Topical	1.12 g/100g
Suppository	Rectal	25 mg/1
Suppository	Rectal	30 mg/1
Solution	Auricular (otic)
Cream	Topical	1 mg/g
Ointment	Topical	1 mg/g
Solution	Topical	1 mg/mL
Cream	Topical	500 mg
Cream	Topical	1 g
Cream	Topical	1.02 g/100g
Cream	Topical	5 mg
Cream	Topical	10 mg
Ointment	Topical	0.5 %
Ointment	Topical	1 %
Cream	Topical	.5 g/100g
Powder, for solution	Intramuscular; Intravenous	100 mg
Powder, for solution	Intramuscular; Intravenous	250 mg
Powder, for solution	Intramuscular; Intravenous	500 mg
Powder, for solution	Intramuscular; Intravenous	1 g
Cream	Topical	140 mg/14g
Cream	Topical	2 mg/g
Ointment	Topical	2 mg/g
Lotion	Topical	1 g/100mL
Cream	Topical	0.2 %
Ointment	Topical	0.2 %
Lotion	Topical	1 g/88mL
Lotion	Topical	1.02 g/100g
Cream	Topical	1 g/100g
Ointment	Topical	1 g/100g
Cream	Topical	.5 %
Cream	Rectal
Cream	Rectal; Topical
Gel	Rectal
Liquid	Topical	5 mg/mL
Liquid	Topical	9 mg/mL
Spray	Topical	10 mg/mL
Cream	Topical	.009 g/1
Suspension	Auricular (otic); Ophthalmic
Solution / drops	Auricular (otic)
Suspension / drops	Auricular (otic)
Ointment	Ophthalmic
Suspension	Ophthalmic
Lotion	Topical	5 mg/g
Lotion	Topical	20 mg/g
Kit
Lipstick	Topical	.005 g/g
Lotion	Topical	.025 mg/2.5mL
Gel	Topical
Cream	Topical	7.5 g/100mL
Lotion	Topical
Ointment	Topical
Cream	Topical
Liquid	Topical	.28 mg/100mL
Aerosol	Rectal
Aerosol, foam	Topical
Ointment	Rectal
Ointment	Rectal; Topical	750 mg
Cream	Topical	.51 g/100g
Spray	Topical	500 g/g
Cream	Topical	1 mg/100mL
Lotion	Topical	2.5 %
Liquid	Topical	10 mg/g
Liquid	Topical
Liquid	Topical	1 g/100mL
Injection, powder, for solution	Intramuscular; Intravascular	100 mg/2mL
Injection, powder, for solution	Intramuscular; Intravenous	100 mg/2mL
Injection, powder, for solution	Intramuscular; Intravenous	1000 mg/8mL
Injection, powder, for solution	Intramuscular; Intravenous	250 mg/2mL
Injection, powder, for solution	Intramuscular; Intravenous	500 mg/4mL
Lotion	Topical	1 mL/100mL
Ointment	Auricular (otic); Ophthalmic
Solution / drops	Ophthalmic
Solution	Topical	25 mg/mL
Lotion	Topical	1 %
Cream	Topical	2 %
Cream	Topical	280 mg/28g
Cream	Topical	1.12 g/100g
Cream	Topical	10 mg/L
Spray	Topical	10 g/L

Prices

Unit description	Cost	Unit
Locoid Lipocream 0.1% Cream 60 gm Tube	335.36USD	tube
Cortifoam 90 mg Foam 15 gm Can	239.99USD	can
Locoid 0.1% Solution 60ml Bottle	233.15USD	bottle
Locoid Lipocream 0.1% Cream 45 gm Tube	200.98USD	tube
Locoid 0.1% Cream 45 gm Tube	183.83USD	tube
Locoid 0.1% Ointment 45 gm Tube	174.86USD	tube
Pandel 0.1% Cream 45 gm Tube	161.37USD	tube
Pandel 0.1% Cream 15 gm Tube	138.56USD	tube
Proctocort 1% Cream 28.35 gm Tube	127.51USD	tube
Anusol-HC 2.5% Cream 30 gm Tube	106.45USD	tube
Locoid Lipocream 0.1% Cream 15 gm Tube	85.41USD	tube
Texacort 2.5% Solution 30ml Bottle	85.41USD	bottle
Cortisporin 3.5-10000-1 Solution 10ml Bottle	84.33USD	bottle
Proctofoam HC 1-1% Foam 10 gm Can	81.9USD	can
Cortisporin 3.5-10000-1 Suspension 10ml Bottle	79.55USD	bottle
Locoid 0.1% Solution 20ml Bottle	79.28USD	bottle
Cortisporin 1% Ointment 15 gm Tube	75.09USD	tube
Locoid 0.1% Cream 15 gm Tube	67.49USD	tube
Hydrocortisone Ace-Pramoxine 2.5-1% Cream 28.35 gm Tube	64.75USD	tube
Locoid 0.1% Ointment 15 gm Tube	62.04USD	tube
Hydrocortisone Valerate 0.2% Ointment 60 gm Tube	56.74USD	tube
Hydrocortisone 2.5% Lotion 59 gm Bottle	55.61USD	bottle
Westcort 0.2% Ointment 60 gm Tube	55.0USD	tube
Cortisporin 0.5-0.5-10000 Cream 7.5 gm Tube	54.37USD	tube
Westcort 0.2% Ointment 15 gm Tube	50.99USD	tube
Hydrocortisone Butyrate 0.1% Cream 45 gm Tube	49.43USD	tube
Hydrocortisone Valerate 0.2% Ointment 45 gm Tube	48.73USD	tube
Hydrocortisone 2.5% Lotion 59ml Bottle	47.47USD	bottle
Westcort 0.2% Ointment 45 gm Tube	46.97USD	tube
Hydrocortisone Valerate 0.2% Cream 60 gm Tube	44.99USD	tube
Hydrocortisone Valerate 0.2% Cream 45 gm Tube	33.99USD	tube
Ala Scalp 2% Lotion 29.6ml Bottle	30.99USD	bottle
Hydrocortisone Valerate 0.2% Ointment 15 gm Tube	30.56USD	tube
Westcort 0.2% Cream 15 gm Tube	25.99USD	tube
Hydrocortisone Valerate 0.2% Cream 15 gm Tube	19.99USD	tube
Cortisporin eye drops	19.74USD	ml
Solu-Cortef 1 g/vial	17.55USD	vial
Hydrocortisone 1% Lotion 118ml Bottle	15.99USD	bottle
Hydrocortisone Acetate 12 25 mg Suppository Box	15.01USD	box
Hydrocortisone 2.5% Ointment 28.35 gm Tube	13.68USD	tube
Hydrocortisone 2.5% Cream 30 gm Tube	13.67USD	tube
Colocort 100 mg/60ml Enema 60ml Bottle	13.15USD	bottle
Hydrocortisone 100 mg/60ml Enema 60ml Bottle	12.6USD	bottle
Hydrocortisone 0.5% Cream 28.35 gm Tube	11.99USD	tube
Hydrocortisone 1% Cream 15 gm Tube	11.99USD	tube
Hydrocortisone 1% Cream 28 gm Tube	11.99USD	tube
Hydrocortisone Acetate 1-1% Ointment 30 gm Tube	11.99USD	tube
Solu-Cortef 500 mg/vial	10.47USD	vial
Hydrocortisone hemisucc powder	9.9USD	g
Cortifoam 10% aerosol	9.35USD	g
Hydrocortisone Sod. Succinate 1 g/vial	9.01USD	vial
Solu-cortef (pf) 250 mg vial	8.58USD	vial
Cortisporin-tc ear susp	8.3USD	ml
Cortisporin ear suspension	7.86USD	ml
Solu-Cortef 250 mg/vial	7.05USD	vial
Cortenema (100 mg/60Ml) 100 mg/enm Enema	6.96USD	enema
Proctofoam-hc foam	6.77USD	g
Cortifoam 10 % Foam	6.14USD	g
Hycort (100 mg/60Ml) 100 mg/enm Enema	5.79USD	enema
Cortamed 2.5 % Ointment	5.67USD	g
Hydrocortisone Sod. Succinate 500 mg/vial	5.34USD	vial
Hydrocortisone powder	5.19USD	g
Solu-cortef (pf) 100 mg vial	4.85USD	vial
Solu-cortef 100 mg vial	4.63USD	vial
Proctocort 1% cream	4.37USD	g
Pandel 0.1% cream	4.34USD	g
Locoid 0.1% lipocream	4.3USD	g
Solu-Cortef 100 mg/vial	4.07USD	vial
Locoid 0.1% cream	3.92USD	g
Hydrocortisone Sod. Succinate 250 mg/vial	3.56USD	vial
Hydrocortisone ss 250 mg vial	3.5USD	vial
Anusol-hc 2.5% cream	3.45USD	g
Hydrocortisone acet powder	3.15USD	g
Proctofoam	2.89USD	g
A-hydrocort 100 mg vial	2.42USD	each
Proctocream-hc 2.5% cream	2.17USD	g
Hydrocortisone Sod. Succinate 100 mg/vial	2.1USD	vial
Hydrocortisone val 0.2% cream	2.07USD	g
Hytone 2.5% cream	1.46USD	g
Hydrocortisone buty 0.1% cream	1.31USD	g
First hydrocort 10% gel	1.18USD	g
Westcort 0.2% cream	1.17USD	g
Procto-kit 1% cream	1.08USD	g
Ala-scalp hp 2% lotion	1.03USD	ml
Cortef 20 mg tablet	0.9USD	tablet
Proctosol-hc 2.5% cream	0.89USD	g
Proctozone-hc 2.5% cream	0.83USD	g
Orabase plain paste	0.77USD	g
Hydrocortisone 2.5% lotion	0.6USD	ml
Cortef 10 mg tablet	0.55USD	tablet
Orabase-b 20% gel	0.55USD	g
Hydrocortisone 2.5% cream	0.53USD	g
Hydrocortisone 10 mg tablet	0.52USD	tablet
Cortef 5 mg tablet	0.45USD	tablet
Ala-cort 1% cream	0.43USD	g
Hydrocortisone 5 mg tablet	0.38USD	tablet
Corticaine 0.5% cream	0.37USD	g
Hydrocortisone 20 mg tablet	0.32USD	tablet
Prevex Hc 1 % Occlusive Cream	0.3USD	g
Emo-Cort 2.5 % Cream	0.26USD	g
Preparation h 1% cream	0.24USD	g
Tucks hydrocortisone ointment	0.24USD	g
Emo-Cort 2.5 % Lotion	0.23USD	g
Emo-Cort Scalp 2.5 % Lotion	0.22USD	g
Colocort 100 mg enema	0.21USD	ml
Cortenema 100 mg enema	0.21USD	ml
Sarna Hc 2.5 % Lotion	0.2USD	g
Emo-Cort 1 % Cream	0.19USD	g
Balneol lotion	0.18USD	ml
Emo-Cort 1 % Lotion	0.18USD	g
Lanacort 1% cool creme	0.18USD	g
Hyderm 0.5 % Cream	0.18USD	g
Hytone 1% cream	0.17USD	g
Cortoderm Mild 0.5 % Ointment	0.15USD	g
Beta hc 1% lotion	0.14USD	ml
Cortizone-10 1% spray	0.14USD	ml
Hydroval 0.2 % Cream	0.13USD	g
Hydroval 0.2 % Ointment	0.13USD	g
Aquanil hc 1% lotion	0.12USD	ml
Hydrocortisone plus 12 1% crm	0.12USD	g
Scalpicin 3% liquid	0.12USD	ml
Slender cortisol capsule	0.12USD	capsule
Cortaid 1% spray	0.1USD	ml
Sarna Hc 1 % Lotion	0.1USD	g
Hydrocortisone 0.5% cream	0.08USD	g
Hydrocortisone 1% cream	0.08USD	g
Uniderm moisturizer	0.05USD	ml
Cortoderm Regular 1 % Ointment	0.04USD	g
Hyderm 1 % Cream	0.04USD	g

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5635497	No	1994-06-03	2014-06-03
US7378405	No	2006-12-19	2026-12-19
US7981877	No	2005-01-23	2025-01-23
USRE39264	No	1996-08-02	2016-08-02
US6514980	No	1999-01-24	2019-01-24
US7223387	No	2001-07-24	2021-07-24